




सत्यमेव जयते

Department of Health Research
Ministry of Health and Family Welfare, Government of India



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911




2022 Edition, Vol.III

STANDARD TREATMENT WORKFLOWS *of India*

PARTNERS





STANDARD
TREATMENT
WORKFLOWS
of India



सत्यमेव जयते

Department of Health Research
Ministry of Health and Family Welfare, Government of India



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

These STWs have been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (stw.icmr.org.in) for more information.

© Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.

Suggested Citation: Standard Treatment Workflows of India, 2022, Edition, Vol. 3, New Delhi, Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India.

© DHR and ICMR

All rights reserved. No part of these workflows may be transmitted or reproduced in any form or by any means without prior permission from the organization.

Printed in India

CONTENTS

- INTRODUCTION
- SPECIALITIES COVERED IN THIS EDITION

• **Haemolytic Anaemia**
Sickle Cell Disease



Department of Health Research
Ministry of Health and Family Welfare, Government of India



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Established in the year 1947

INTRODUCTION


GOAL

To empower the primary, secondary and tertiary health care physicians/surgeons towards achieving the overall goal of Universal Health Coverage with disease management protocols and pre-defined referral mechanisms by decoding complex guidelines.


OBJECTIVES


To formulate treatment algorithms for common and serious medical & surgical conditions for both outdoor & indoor patient management at primary, secondary and tertiary levels of India's healthcare system that are scientific, robust and locally contextual.

METHODOLOGY



PROCESS OVERVIEW





HAEMOLYTIC ANAEMIA



Standard Treatment Workflow (STW)


SICKLE CELL DISEASE

ICD-10-D57

GENERAL INTRODUCTION

- Hemolytic anemia, where RBCs sickle under hypoxia or stress. Sickling and inflammation lead to vaso-occlusive crisis (VOC) and organ damage
- Autosomal recessive - mutations in the β -globin gene
- ~88% of sickle homozygous cases in Asia are Indians

SUBTYPES




MANIFESTATIONS OF VOC

- Experienced as pain, or swelling
- Each VOC can lead to long lasting problems and end-organ damage
- Typical sites - hands and feet, limbs, abdominal viscera, ribs, sternum etc
- The crisis is usually precipitated by fever, strenuous exercise, dehydration, drenching in rain, surgery, infection etc.

THIS FAMILY TREE SHOWS THROUGH MENDELIAN TRANSMISSION - THE RISK OF HAVING AFFECTED CHILDREN ACROSS GENERATION IN PARENTS WITH SCD - HETEROZYGOUS AND HOMOZYGOUS.

LEGEND

- Half red color – one affected allele - carrier (HbAS)
- Full red color – two affected alleles - homozygous/diseased (HbSS)
- No red color – both alleles normal



CLINICAL MANIFESTATIONS OF SCD

- Common presentations - Pain, anemia, icterus, increased risk of infection
- Acute morbidity/ events - Splenic sequestration, fatigue, acute chest syndrome, priapism
- Long term complications - End organ damage, hepatopathy, chronic kidney disease, hypersplenism, avascular necrosis of femur, osteomyelitis, pulmonary hypertension, cholelithiasis, functional disability, retinopathy, foot ulcers- refer to a higher center for adequate management

Target group to be screened

Antenatal Mothers or pre-pregnancy planning

Tests / remarks

- CBC all women in first trimester
- In endemic pockets/ high risk population: solubility test/ POC tests for sickle cell
- Or HPLC and electrophoresis, if available
 - » If mother is a sickle cell carrier/ disease, then testing of father is mandatory,
 - » Ideally by HPLC, if not available refer to higher center
 - » If father tests positive, counselling and pre-natal testing should be performed (at centers with necessary facilities) to prevent risk of birth of affected newborn

Newborn

- POC tests to initiate penicillin prophylaxis in baby and enrolling vaccination program
- HPLC and electrophoresis, if available or at later date

Population screening/ patient of any age

- In endemic pockets/ high risk population: solubility test/ POC tests for sickle cell

GENERAL PRINCIPALS OF MANAGEMENT

- Carriers are usually asymptomatic and needs no treatment
- The goal of management is to improve quality of life and life expectancy of the affected individuals
- Episodes of fever have to be dealt with early and aggressively
- Early and aggressive management of pain should be advocated, since pain may be indicative of microvascular organ damage. Pain management using paracetamol, diclofenac or tramadol. For severe pain, refer to higher centre
- Malaria in SCD patients will be present with same frequency as endemic prevalence
- Evaluate for anaemia. Iron supplements for anemia to be used cautiously (low dose - not more than 3 months). Other nutritional causes (Vit B12, and Folic acid deficiency) and infectious causes (worm infestations) to be evaluated
- Prophylaxis for infections- penicillin, immunizations and folic acid supplement, disease modifying agents like hydroxyurea (HU) and blood transfusions have specific indications
- Acute morbidity events occur over the lifetime and require management, regular monitoring may help to reduce severity of complications
- Only curative therapy is hematopoietic stem cell transplantation. This is recommended and beneficial in a small subset of patients not responding to HU or newer disease modifying agents

PROPHYLAXIS FOR ALL SCD PATIENTS

New born HbSS till 5 years of age	Penicillin prophylaxis- 65mg BD, less than 12 months 125 mg BD till 2 years , then 250mg BD till 5 years lifelong if post splenectomy
To prevent megaloblastic crises	Folic acid- less than 1 year of age, 2.5 mg daily 1 year of age, 5 mg daily
Common recommended vaccinations	Pneumococcal Vaccine H-influenza vaccine Typhoid Vaccine Influenza vaccine COVID 19 vaccine

HOW TO PRESCRIBE HYDROXYUREA

Indications for HU	Baseline Investigations	Dosing	Toxicity
<ul style="list-style-type: none"> • Above 2 years of Age • All children more than 9 months of age may be offered 	<ul style="list-style-type: none"> • Complete physical Examination • CBC • Liver function test • Renal function • Pregnancy test for relevant population 	<ul style="list-style-type: none"> • Infants and Children: 10-15 mg/kg/day • Adolescents: 15mg/kg/day • Dose escalation by 5 mg/kg; 2-3 months only in definite indications • CBC monitoring 1-3 months when starting the medicine or if dose change 	<ul style="list-style-type: none"> • Common dose dependent toxicity: anaemia, nausea, diarrhoea, gastritis • Nail/ skin hyperpigmentation • Long term toxicity: Mucositis or leg ulcers

Red Flag for hospitalization or referral to higher centre

- Acute illness requiring immediate medical care, including emergencies
- Persistent Temperature $>38^{\circ}\text{C}$
- Pain inadequately relieved by home measures
- Significant respiratory symptoms (cough, shortness of breath, chest pain) or hypoxia
- Abdominal pain, distention, acute enlargement of spleen
- Any neurological signs or symptoms
- Significant increase in pallor, fatigue, lethargy
- Significant vomiting and diarrhoea

EDUCATION AND GENETIC COUNSELING

- **Medical disease counselling** - Explain the clinical presentation, severity, consequences of the disease. Importance of early diagnosis by newborn screening and comprehensive care. Teach patients and parents - avoid infections, be adequately hydrated, balanced nutrition, avoid over exercise, avoid extreme temperatures, importance of penicillin prophylaxis, need for regular clinical follow up of patients
- **Genetic counselling** - Explain carrier state and risk of having an affected child. Document family history, consanguinity, draw a pedigree chart, explain the inheritance pattern and risk of recurrence
- **Preconception care counselling** - for at-risk couples by following recommended practices. Give options and referrals
- **Pre and post test support to the family** - while making decisions and eliminating irrational fears, stigmatization, maintaining confidentiality
- **Cascade screening** - Emphasize the need for screening of extended family members

EARLY AND AGGRESSIVE MANAGEMENT OF PAIN AND INFECTIONS WILL HELP IMPROVE LONG TERM OUTCOME

CONTRIBUTORS

ADVISORY COMMITTEE

CHAIRMAN

Prof. (Dr.) Balram Bhargava, Secretary-DHR and DG-ICMR

VICE CHAIRMAN

Dr. Nikhil Tandon, AIIMS, New Delhi

MEMBERS

Dr. Anil Bhansali, Endocrinology, PGIMER, Chandigarh

Mrs. Anu Nagar, Jt. Secretary, Dept. of Health Research, MoHFW, Govt. of India

Dr. Ashok Deorari, Neonatology, AIIMS, New Delhi

Dr. Binod K Khaitan, Dermatology, AIIMS, New Delhi

Dr. Pramod Garg, Gastroenterology, TISHTI, Faridabad

Dr. Radhika Tandon, Ophthalmology, AIIMS, New Delhi

Dr. Rajdeep Singh, General Surgery, MAMC, New Delhi

Dr. S. C. Goel, Orthopaedics, BHU, Varanasi

Dr. Sandeep Agarwala, Paediatrics, AIIMS, New Delhi

Dr. Sudeep Gupta, Oncology, TMC, Mumbai

Dr. T. Sundararaman, Former Executive Director, NHSRC, New Delhi

Dr. Usha Dutta, Gastroenterology, PGIMER, Chandigarh

Ex officio Additional Secretary & MD (NHM), MoHFW, Govt. of India

Ex officio Director General Health Services / Representative

EDITORIAL BOARD

EXTERNAL COMMITTEE

Dr. Anil Bhansali, Endocrinology, PGIMER, Chandigarh

Dr. Anurag Srivastava, Oncology, AIIMS, New Delhi

Dr. Deepika Pandhi, Dermatology, UCMS, New Delhi

Dr. Neeraj Gupta, Paediatrics, AIIMS, Jodhpur

Dr. Radhika Tandon, Ophthalmology, RP Centre, AIIMS, New Delhi

Dr. Rajdeep Singh, General Surgery, MAMC, New Delhi

Dr. Usha Dutta, Gastroenterology, PGIMER, Chandigarh

Dr. Vijay Jain, Orthopaedics, RML, New Delhi

INTERNAL COMMITTEE

Dr. R S Dhaliwal, Scientist G & Head (NCD), ICMR

Dr. Ashoo Grover, Scientist F, ICMR

Dr. Lokesh Kumar Sharma, Scientist E, ICMR

Dr. Aparna Mukherjee, Scientist E, ICMR

Dr. Jerin Jose Cherian, Scientist D, ICMR

Dr. Saumya Srivastava Aggarwal, Project Scientist C, ICMR



Department of Health Research
Ministry of Health and Family Welfare, Government of India



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
SERVING THE NATION SINCE 1952

EXPERT GROUPS

SICKLE CELL DISEASE

CHAIR

Dr. Tulika Seth, AIIMS, New Delhi

MEMBERS

Dr. Dipti Jain, GMC, Nagpur

Dr. Manisha Madkaikar, ICMR-NIIH, Mumbai

Dr. N S Chatterjee, ICMR, New Delhi

Dr. P K Patra, CCMMC, Durg

Dr. Roshan Colah, ICMR-NIIH, Mumbai (Retired)

CHIEF PATRON

Dr Mansukh Mandaviya

Union Minister for Health & Family Welfare

PATRON

Dr Bharati Pravin Pawar

Union Minister of State for Health & Family Welfare

ADVISOR

Prof. Dr Balram Bhargava

Secretary, DHR & Director General, ICMR

ICMR STW TEAM

Dr R S Dhaliwal, Scientist G & Head(NCD), ICMR

Dr Ashoo Grover, Scientist F, ICMR

Dr Lokesh Kumar Sharma, Scientist E, ICMR

Dr Jerin Jose Cherian, Scientist D, ICMR

Mr Neeraj Parmar, Technical Officer A, ICMR

Dr Saumya Srivastava Aggarwal, Project Scientist C, ICMR

Mr Dhiraj Kumar, Project Graphics Designer, ICMR

ADMINISTRATION


Shri R. Ramakrishnan, Sr DDG (Admin.), ICMR

Shri Rajeev Roy, Sr FA, ICMR

Dr R Lakshminarayanan, DDG(Admin.), ICMR

Shri Jagdish Rajesh, ADG (Admin.), ICMR

Shri Vinod Sharma, ADG(Finance), ICMR



STANDARD
TREATMENT
WORKFLOWS
of India

Scan to access Standard Treatment Workflows



Web Portal



Google Play



App Store



Department of Health Research
Ministry of Health and Family Welfare, Government of India



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

STANDARD TREATMENT WORKFLOWS *of India*



PARTNERS



2022 EDITION
VOLUME III